Related Experiment Video
Updated: Jul 3, 2026

Cardiac Magnetic Resonance for the Evaluation of Suspected Cardiac Thrombus: Conventional and Emerging Techniques
Published on: June 11, 2019
Contrast agents: magnetic resonance
Carmen Burtea1, Sophie Laurent, Luce Vander Elst
1Department of General, Organic and Biomedical Chemistry, NMR and Molecular Imaging Laboratory, University of Mons-Hainaut, 24, Avenue du Champ de Mars, 7000, Mons, Belgium. carmen.burtea@umh.ac.be
Abstract:
Even though the intrinsic magnetic resonance imaging (MRI) contrast is much more flexible than in other clinical imaging techniques, the diagnosis of several pathologies requires the involvement of contrast agents (CAs) that can enhance the difference between normal and diseased tissues by modifying their intrinsic parameters. MR CAs are indirect agents because they do not become visible by themselves as opposed to other imaging modalities. The signal enhancement produced by MRI CAs (i.e., the efficiency of the CAs) depends on their longitudinal (r1) and transverse (r2) relaxivity (expressed in s(-1) mmol(-1) 1), which is defined as the increase of the nuclear relaxation rate (the reciprocal of the relaxation time) of water protons produced by 1 mmol per liter of CA. Paramagnetic CAs (most of them complexes of gadolinium) are frequently used in clinics as extracellular, hepatobiliary or blood pool agents. Low molecular weight paramagnetic CAs have similar effects on R1 and R2, but the predominant effect at low doses is that of T1 shortening (and R1 enhancement). Thus, organs taking up such agents will become bright in a T1-weighted MRI sequence; these CAs are thus called positive contrast media. The CAs known as negative agents influence signal intensity mainly by shortening T2* and T2, which produces the darkening of the contrast-enhanced tissue. These CAs are generally composed of superparamagnetic nanoparticles, consisting of iron oxides (magnetite, Fe3O4, maghemite, gammaFe2O3, or other ferrites). Iron oxide nanoparticles are taken up by the monocyte-macrophage system, which explains their potential application as MRI markers of inflammatory and degenerative disorders. Most of the contemporary MRI CAs approved for clinical applications are non-specific for a particular pathology and report exclusively on the anatomy and the physiological status of various organs. A new generation of MRI CAs is progressively emerging in the current context of molecular imaging, agents that are designed to detect with a high specificity the cellular and molecular hallmarks of various pathologies.
Insights
Magnetic resonance imaging (MRI) contrast agents enhance tissue differences for pathology diagnosis. New molecular imaging agents offer increased specificity for detecting disease hallmarks.
Area of Science:
- Medical Imaging
- Biomedical Engineering
- Radiology
Background:
- Magnetic resonance imaging (MRI) contrast agents (CAs) are crucial for enhancing diagnostic accuracy by modifying tissue parameters.
- Unlike other modalities, MR CAs are indirect, influencing water proton relaxation rates (R1 and R2) rather than being directly visible.
- Current CAs, often gadolinium-based or iron oxide nanoparticles, offer broad applications but lack pathological specificity.
Purpose of the Study:
- To review the mechanisms and applications of current MRI contrast agents.
- To highlight the limitations of existing non-specific CAs in diagnosing pathologies.
- To introduce the emerging field of molecular imaging and its potential for developing specific MRI contrast agents.
Main Methods:
- Review of existing literature on MRI contrast agent mechanisms and classifications.
- Analysis of relaxivity (r1 and r2) principles for positive (T1 shortening) and negative (T2/T2* shortening) contrast enhancement.
- Discussion of nanoparticle uptake and targeting strategies for advanced imaging.
Main Results:
- Paramagnetic CAs (e.g., gadolinium) primarily cause T1 shortening, leading to positive contrast (brightening on T1-weighted images).
- Superparamagnetic iron oxide nanoparticles induce T2/T2* shortening, resulting in negative contrast (darkening).
- Contemporary CAs are generally non-specific, providing anatomical and physiological information.
Conclusions:
- A new generation of MRI contrast agents is being developed for molecular imaging.
- These advanced agents aim to detect specific cellular and molecular markers of disease with high precision.
- The future of MRI contrast agents lies in targeted, specific detection for improved pathological diagnosis.
Related Concept Videos
Magnetic Resonance Imaging
Imaging Studies for Cardiovascular System IV: CMRI
Imaging Studies I: CT and MRI
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
Imaging Studies IV: Magnetic Resonance Imaging
Imaging Studies for Cardiovascular System V: CT
Imaging Studies III: Computed Tomography

